Bookmark
Forward
QuickView for Metolazone (compound)
PubChem
| Name: | Metolazone |
|---|---|
| PubChem Compound ID: | 11957638 |
| Description: | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic RENAL FAILURE. It also tends to lower BLOOD PRESSURE and increase POTASSIUM loss. |
| Molecular formula: | C16H16ClN3O3S |
| Molecular weight: | 365.835 g/mol |
| Synonyms: |
EU-0100833
|
DrugBank
Identification
| Name: | Metolazone |
|---|---|
| Name (isomeric): | DB00524 |
| Drug Type: | small molecule |
| Description: | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic RENAL FAILURE. It also tends to lower BLOOD PRESSURE and increase POTASSIUM loss. |
| Synonyms: |
Metolazona [INN-Spanish]; Metolazonum [INN-Latin]
|
| Brand: | Diulo, Zaroxolyn, Mykrox, Metalozone, Microx, Metalazone, Oldren, Metenix, Xuret |
| Category: | Diuretics, Sulfamyl, Diuretics, Antihypertensive Agents |
| CAS number: | 17560-51-9 |
Pharmacology
| Indication: | For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. |
|---|---|
| Pharmacology: |
Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has bee...
show more » |
| Mechanism of Action: |
The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased del...
show more » |
| Absorption: | Peak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent. |
| Protein binding: | 50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound |
| Biotransformation: | Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling. |
| Route of elimination: | Most of the drug is excreted in the unconverted form in the urine. |
| Half Life: | Approximately 14 hours. |
| Toxicity: | Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
